Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cryosite Limited ( (AU:CTE) ) is now available.
Cryosite Limited reported a 12% increase in revenue to $14.1 million for the fiscal year ending June 30, 2025, with a 21% rise in profit before tax. The company experienced stronger trading conditions in the latter half of the year, contributing to a 19% increase in EBITDA. Despite these gains, the company decided not to declare a dividend for FY25, opting instead to focus on expansion plans, including securing a second facility to support future growth. This strategic decision is backed by a strong balance sheet and robust cash flows, allowing Cryosite to expand without raising additional capital.
The most recent analyst rating on (AU:CTE) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
More about Cryosite Limited
Cryosite Limited operates in the biotechnology industry, focusing on the storage and management of biological materials. The company provides services related to the preservation of biological specimens, catering to clients in the medical and research sectors.
Average Trading Volume: 6,948
Technical Sentiment Signal: Buy
Current Market Cap: A$36.61M
For a thorough assessment of CTE stock, go to TipRanks’ Stock Analysis page.